Treatment of childhood kaposiform hemangioendothelioma with sirolimus

Julie Blatt, Joseph Stavas, Billie Moats-Staats, John Woosley, Dean S. Morrell

Research output: Contribution to journalArticle

96 Scopus citations

Abstract

Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.

Original languageEnglish
Pages (from-to)1396-1398
Number of pages3
JournalPediatric Blood and Cancer
Volume55
Issue number7
DOIs
StatePublished - Dec 2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Fingerprint Dive into the research topics of 'Treatment of childhood kaposiform hemangioendothelioma with sirolimus'. Together they form a unique fingerprint.

  • Cite this

    Blatt, J., Stavas, J., Moats-Staats, B., Woosley, J., & Morrell, D. S. (2010). Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatric Blood and Cancer, 55(7), 1396-1398. https://doi.org/10.1002/pbc.22766